金活醫藥集團(01110.HK)年度純利預降70%-75%
格隆匯 3 月 22日丨金活醫藥集團(01110.HK)公佈,集團預期於截至2020年12月31日止年度的公司擁有人應占溢利將較上年度的人民幣4340萬元減少約70%至75%。
董事會認為公司擁有人應占溢利減少主要是由於以下因素:
(i)受新型冠狀病毒(COVID-19)疫情的影響,到訪香港的旅客人數大幅下降,加上香港消費氣氛疲弱,集團康萃樂益生菌產品系列於香港及澳門市場2020年度的總收益較上年度同期下跌約70%至75%;及
(ii)集團2020年度的行政開支較上年度的人民幣1.074億元增加約35%至40%,主要由於集團於2020年度的康萃樂益生菌產品系列銷售下跌,導致相關舊存貨撥備增加。
董事會亦謹此知會,於2020年度,(i)公司的非全資附屬公司,深圳市東迪欣科技有限公司("東迪欣");及(ii)集團之投資項目,包括參股東華通投資有限公司("東華通")15%股權,都能為集團帶來溢利。東迪欣為一家生產各種醫療設備(包括紅外線探熱器)的醫療設備製造商,並已為其製造的醫療設備取得各項證書及許可證。東華通主要是間接參股米蓋爾公司*(一間從事食品分銷、批發及供應鏈管理的西班牙公司)及澳大利亞瑪納森食品公司*(一間大型食品公司)。
基於上文所述,集團預期2020年度的集團溢利將較上年度的人民幣5030萬元增加約1%至5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.